Skip to main content
NCBI home page
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1992;70(6):757–767.

Cost-benefit analysis of a nationwide inoculation programme against viral hepatitis B in an area of intermediate endemicity.

G M Ginsberg 1, S Berger 1, D Shouval 1
PMCID: PMC2393399  PMID: 1486673

Abstract

The large decrease in the cost of vaccines against hepatitis virus B prompts a re-examination of nationwide vaccination campaign strategies. The present study estimates the costs and benefits that would result from a viral hepatitis B prevention programme (with no prior screening) targeted at all under-16-year-olds in Israel in 1990 and only neonates in the period 1991-2034. Israel is situated in an area of intermediate endemicity, where the majority of HBsAg carriers are anti-HBe positive. Such a policy would reduce the number of cases of viral hepatitis B in the vaccinated cohort from 654,000 to 270,000 over the period 1990-2059, yielding a benefit-to-cost ratio of 1.88: 1 for the health services only. Inclusion also of the indirect benefits of reduced work absences and mortality would increase the benefit-to-cost ratio to 2.77:1. Even when the benefits arising from the reduction in hepatocellular carcinoma and liver transplants were excluded, the benefit-to-cost ratio for the health services alone would still be 1.41:1. The adoption of such a nationwide inoculation policy appears therefore to be not only medically but also economically justifiable.

Full text

PDF
757

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler M. W., Belsey E. M., McCutchan J. A., Mindel A. Should homosexuals be vaccinated against hepatitis B virus? Cost and benefit assessment. Br Med J (Clin Res Ed) 1983 May 21;286(6378):1621–1624. doi: 10.1136/bmj.286.6378.1621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alter M. J., Coleman P. J., Alexander W. J., Kramer E., Miller J. K., Mandel E., Hadler S. C., Margolis H. S. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA. 1989 Sep 1;262(9):1201–1205. [PubMed] [Google Scholar]
  3. André F. E. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med. 1989 Sep 4;87(3A):14S–20S. doi: 10.1016/0002-9343(89)90525-1. [DOI] [PubMed] [Google Scholar]
  4. Arevalo J. A., Washington A. E. Cost-effectiveness of prenatal screening and immunization for hepatitis B virus. JAMA. 1988 Jan 15;259(3):365–369. [PubMed] [Google Scholar]
  5. Barbara J. A., Howell D. R., Contreras M., Tedder R. S., Briggs M., Sanderson P. J., Wood J., Bevan G. Indications for hepatitis B immunoglobulin for neonates of HBsAg carrier mothers. Br Med J (Clin Res Ed) 1984 Oct 6;289(6449):880–880. doi: 10.1136/bmj.289.6449.880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Beasley R. P., Hwang L. Y., Lee G. C., Lan C. C., Roan C. H., Huang F. Y., Chen C. L. Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine. Lancet. 1983 Nov 12;2(8359):1099–1102. doi: 10.1016/s0140-6736(83)90624-4. [DOI] [PubMed] [Google Scholar]
  7. Beasley R. P., Hwang L. Y., Lin C. C., Chien C. S. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981 Nov 21;2(8256):1129–1133. doi: 10.1016/s0140-6736(81)90585-7. [DOI] [PubMed] [Google Scholar]
  8. Beasley R. P., Hwang L. Y., Lin C. C., Stevens C. E., Wang K. Y., Sun T. S., Hsieh F. J., Szmuness W. Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised double-blind placebo-controlled trial. Lancet. 1981 Aug 22;2(8243):388–393. doi: 10.1016/s0140-6736(81)90832-1. [DOI] [PubMed] [Google Scholar]
  9. Beasley R. P., Hwang L. Y., Stevens C. E., Lin C. C., Hsieh F. J., Wang K. Y., Sun T. S., Szmuness W. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology. 1983 Mar-Apr;3(2):135–141. doi: 10.1002/hep.1840030201. [DOI] [PubMed] [Google Scholar]
  10. Ben-Porath E., Enat R., Gruia M., Satinger Y. [Etiology of acute viral hepatitis in Israel]. Harefuah. 1985 Jun 16;108(12):583–585. [PubMed] [Google Scholar]
  11. Bogomolski-Yahalom V., Granot E., Linder N., Adler R., Korman S., Manny N., Tur-Kaspa R., Shouval D. Prevalence of HBsAg carriers in native and immigrant pregnant female populations in Israel and passive/active vaccination against HBV of newborns at risk. J Med Virol. 1991 Aug;34(4):217–222. doi: 10.1002/jmv.1890340404. [DOI] [PubMed] [Google Scholar]
  12. Chemtob D., Fassberg J., Kalka I., Harlap S., Slater P. E., Ever-Hadani P., Larouze B. Prevention strategy of hepatitis B virus infection among the Ethiopian community in Israel. Isr J Med Sci. 1991 May;27(5):273–277. [PubMed] [Google Scholar]
  13. Davidson M., Krugman S. Recombinant yeast hepatitis B vaccine compared with plasma-derived vaccine: immunogenicity and effect of a booster dose. J Infect. 1986 Jul;13 (Suppl A):31–38. doi: 10.1016/s0163-4453(86)92653-8. [DOI] [PubMed] [Google Scholar]
  14. Dudley F. J., Scheuer P. J., Sherlock S. Natural history of hepatitis-associated antigen-positive chronic liver disease. Lancet. 1972 Dec 30;2(7792):1388–1393. doi: 10.1016/s0140-6736(72)92963-7. [DOI] [PubMed] [Google Scholar]
  15. Eliakim M. Epidemiology of viral hepatitis in Israel, 1978. Isr J Med Sci. 1979 Mar;15(3):248–256. [PubMed] [Google Scholar]
  16. Fattal B. [Infectious disease morbidity in Kibbutzim]. Harefuah. 1988 Sep;115(5-6):111–115. [PubMed] [Google Scholar]
  17. Ginsberg G. M., Tulchinsky T. H. Costs and benefits of a second measles inoculation of children in Israel, the West Bank, and Gaza. J Epidemiol Community Health. 1990 Dec;44(4):274–280. doi: 10.1136/jech.44.4.274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Greenfield C., Osidiana V., Karayiannis P., Galpin S., Musoke R., Jowett T. P., Mati P., Tukei P. M., Thomas H. C. Perinatal transmission of hepatitis B virus in Kenya: its relation to the presence of serum HBV-DNA and anti-HBe in the mother. J Med Virol. 1986 Jun;19(2):135–142. doi: 10.1002/jmv.1890190205. [DOI] [PubMed] [Google Scholar]
  19. Hwang L. Y., Roggendorf M., Beasley R. P., Deinhardt F. Perinatal transmission of hepatitis B virus: role of maternal HBeAg and anti-HBc IgM. J Med Virol. 1985 Mar;15(3):265–269. doi: 10.1002/jmv.1890150307. [DOI] [PubMed] [Google Scholar]
  20. Jönsson B. Cost-benefit analysis of hepatitis B vaccination. Postgrad Med J. 1987;63 (Suppl 2):27–32. [PubMed] [Google Scholar]
  21. Kane M. A., Hadler S. C., Margolis H. S., Maynard J. E. Routine prenatal screening for hepatitis B surface antigen. JAMA. 1988 Jan 15;259(3):408–409. [PubMed] [Google Scholar]
  22. Kark J. D., Bar-Shani S. Hepatitis A antibody in Israel Defence Forces recruits. J Med Virol. 1981;6(4):341–345. doi: 10.1002/jmv.1890060409. [DOI] [PubMed] [Google Scholar]
  23. Krausz Y., Melamed S., Sandler S. G., Eliakim M. A comparative study of hepatitis B and non-B in hospitalized adults in an endemic area. Isr J Med Sci. 1977 Jan;13(1):9–14. [PubMed] [Google Scholar]
  24. Lahaye D., Strauss P., Baleux C., van Ganse W. Cost-benefit analysis of hepatitis-B vaccination. Lancet. 1987 Aug 22;2(8556):441–443. doi: 10.1016/s0140-6736(87)90971-8. [DOI] [PubMed] [Google Scholar]
  25. Lange W., Masihi K. N. Epidemiology and economic importance of hepatitis B in the Federal Republic of Germany. Postgrad Med J. 1987;63 (Suppl 2):21–26. [PMC free article] [PubMed] [Google Scholar]
  26. London W. T. Primary hepatocellular carcinoma--etiology, pathogenesis, and prevention. Hum Pathol. 1981 Dec;12(12):1085–1097. doi: 10.1016/s0046-8177(81)80329-2. [DOI] [PubMed] [Google Scholar]
  27. Maupas P., Chiron J. P., Barin F., Coursaget P., Goudeau A., Perrin J., Denis F., Mar I. D. Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal). Lancet. 1981 Feb 7;1(8215):289–292. doi: 10.1016/s0140-6736(81)91908-5. [DOI] [PubMed] [Google Scholar]
  28. McMahon B. J., Rhoades E. R., Heyward W. L., Tower E., Ritter D., Lanier A. P., Wainwright R. B., Helminiak C. A comprehensive programme to reduce the incidence of hepatitis B virus infection and its sequelae in Alaskan natives. Lancet. 1987 Nov 14;2(8568):1134–1136. doi: 10.1016/s0140-6736(87)91557-1. [DOI] [PubMed] [Google Scholar]
  29. Mulley A. G., Silverstein M. D., Dienstag J. L. Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis. N Engl J Med. 1982 Sep 9;307(11):644–652. doi: 10.1056/NEJM198209093071103. [DOI] [PubMed] [Google Scholar]
  30. Naggan L., Bar-Shany S., Shmuelewitz O., Finzi M., Prywes R. Prevalence of hepatitis B markers (HBsAg and HBsAb) in women screened at time of delivery. Isr J Med Sci. 1980 May;16(5):347–350. [PubMed] [Google Scholar]
  31. Nayak N. C., Dhar A., Sachdeva R., Mittal A., Seth H. N., Sudarsanam D., Reddy B., Wagholikar U. L., Reddy C. R. Association of human hepatocellular carcinoma and cirrhosis with hepatitis B virus surface and core antigens in the liver. Int J Cancer. 1977 Nov 15;20(5):643–654. doi: 10.1002/ijc.2910200502. [DOI] [PubMed] [Google Scholar]
  32. Polakoff S., Tillett H. E. Acute viral hepatitis B: laboratory reports 1975-9. Br Med J (Clin Res Ed) 1982 Jun 19;284(6332):1881–1882. [PMC free article] [PubMed] [Google Scholar]
  33. Reisler D. M., Brachott D., Mosley J. W. Viral hepatitis in Israel: morbidity and mortality data. Am J Epidemiol. 1970 Jul;92(1):62–72. doi: 10.1093/oxfordjournals.aje.a121180. [DOI] [PubMed] [Google Scholar]
  34. Shalit M., Tur-Kaspa R., Adler R., Manny N., Shraga S., Morag A., Eliakim M. Non-A, non-B hepatitis not following transfusion: a study of hospital patients in Jerusalem. Isr J Med Sci. 1982 Oct;18(10):986–989. [PubMed] [Google Scholar]
  35. Shouval D., Tur-Kaspa R., Adler R., Mani N., Penchas S., Roggendorf M., Frosner G., Eliakim M. Study of 90 hepatitis B surface antigen carriers in Israel. Isr J Med Sci. 1981 Jun;17(6):407–412. [PubMed] [Google Scholar]
  36. Szmuness W., Stevens C. E., Harley E. J., Zang E. A., Oleszko W. R., William D. C., Sadovsky R., Morrison J. M., Kellner A. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980 Oct 9;303(15):833–841. doi: 10.1056/NEJM198010093031501. [DOI] [PubMed] [Google Scholar]
  37. Szmuness W., Stevens C. E., Zang E. A., Harley E. J., Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology. 1981 Sep-Oct;1(5):377–385. doi: 10.1002/hep.1840010502. [DOI] [PubMed] [Google Scholar]
  38. Tolsma D. D., Bryan J. A. The economic impact of viral hepatitis in the United States. Public Health Rep. 1976 Jul-Aug;91(4):349–353. [PMC free article] [PubMed] [Google Scholar]
  39. Tulchinsky T. H., Abed Y., Ginsberg G., Shaheen S., Friedman J. B., Schoenbaum M. L., Slater P. E. Measles in Israel, the West Bank, and Gaza: continuing incidence and the case for a new eradication strategy. Rev Infect Dis. 1990 Sep-Oct;12(5):951–958. doi: 10.1093/clinids/12.5.951. [DOI] [PubMed] [Google Scholar]
  40. Wainwright R. B., McMahon B. J., Bulkow L. R., Hall D. B., Fitzgerald M. A., Harpster A. P., Hadler S. C., Lanier A. P., Heyward W. L. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA. 1989 Apr 28;261(16):2362–2366. [PubMed] [Google Scholar]
  41. Zajac B. A., West D. J., McAleer W. J., Scolnick E. M. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect. 1986 Jul;13 (Suppl A):39–45. doi: 10.1016/s0163-4453(86)92668-x. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES